The MERCURI trial
MEtabolic and Renal outcomes in Cardiac sUrgery patients Receiving SGLT2 Inhibitors
Trial Registry
Summary
Cardiac surgery often leads to acute kidney injury (AKI), with no current effective prevention. We tested whether SGLT2 inhibitors, typically used for diabetes, could reduce this risk. In this study, 60 patients undergoing elective heart surgery were randomly assigned to receive either the SGLT2 inhibitor empagliflozin or standard care. The empagliflozin group received the medication three days before and two days after surgery. Results showed a significantly lower rate of AKI in the empagliflozin group (20%) compared to the control group (66.7%). There were no significant differences in side effects between the groups. This suggests empagliflozin could help prevent AKI in heart surgery patients, warranting further research.
